Related Experiment Videos
[Clinical studies on flomoxef in the perinatal period infections]
T Chimura1, N Morisaki, T Funayama
1Department of Obstetrics & Gynecology, School of Medicine, Yamagata University.
Abstract:
We conducted clinical efficacy and safety tests of flomoxef (FMOX, 6315-S) in the perinatal infections and obtained the following results. 1. A total of 25 patients was treated: 16 patients with intrauterine infections, 2 patients with pelvioperitonitis, 4 patients with urinary tract infections and 3 patients with other infections. FMOX was injected at a daily dose of 2-4 g for 3-15 days (6-60 g for total dose) by intravenous drip infusion, intravenous injection or their combination. 2. The clinical efficacy rate was 96.0% of 25 patients: excellent in 4 cases (16.0%), good in 20 cases (80.0%) and poor in 1 case (4.0%). Bacteriological effects obtained were: eradicated in 14/16 cases (87.5%) replaced in 3 cases. 3. There were no subjective or objective side effects, nor were any abnormal laboratory test values attributable to the drug. From these findings, we consider that FMOX treatment appears to obtain good clinical and bacteriological responses and in safe in perinatal period infections.
Insights
Flomoxef (FMOX) demonstrated high clinical and bacteriological efficacy in treating perinatal infections. This antibiotic was found to be safe and effective for pregnant patients during this critical period.
Area of Science:
- Infectious Diseases
- Pharmacology
- Obstetrics & Gynecology
Context:
- Perinatal infections pose significant risks to both mother and child.
- Effective and safe antimicrobial agents are crucial during pregnancy.
Purpose:
- To evaluate the clinical efficacy and safety of flomoxef (FMOX) in patients with perinatal infections.
- To assess the bacteriological response to FMOX treatment in this population.
Summary:
- A total of 25 patients with various perinatal infections received flomoxef (FMOX) at daily doses of 2-4g.
- The overall clinical efficacy rate was 96.0%, with excellent or good responses in 96% of patients.
- Bacteriological eradication was achieved in 87.5% of cases, with no reported drug-related side effects or abnormal lab values.
Impact:
- Flomoxef (FMOX) shows promise as a safe and effective treatment option for perinatal infections.
- The findings support the use of FMOX in obstetric settings, contributing to improved maternal and infant outcomes.